Entera Bio (ENTX) Revenue (2018 - 2025)

Entera Bio's (ENTX) quarterly Revenue came in at $42000.0 in Q1 2025, down 48.78% on a QoQ basis from $82000.0 in Q4 2024.

Entera Bio (ENTX) Revenue (2018 - 2025) Analysis & Trends

Entera Bio (ENTX) has 7 years of Revenue data on file, last reported at $42000.0 in Q1 2025.

Quarterly Revenue changed N/A year-over-year to $42000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $42000.0 (down 76.8% YoY) and the FY2025 annual result came in at $42000.0, down 76.8% from the prior year.
Revenue declined to $42000.0 in Q1 2025, from $82000.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $165000.0 in Q4 2021 to a low of $8000.0 in Q3 2022.
A 4-year average of $77333.3 and a median of $62500.0 in 2022 frame the typical range for Revenue.
Annual changes were most pronounced in 2021 — Revenue soared 109.62% — and 2022, when it plunged 94.29%.
Tracing ENTX's Revenue over 4 years: stood at $165000.0 in 2021, then slumped by 91.52% to $14000.0 in 2022, then jumped by 485.71% to $82000.0 in 2024, then tumbled by 48.78% to $42000.0 in 2025.
The last three Revenue figures came in at $42000.0 (Q1 2025), $82000.0 (Q4 2024), and $42000.0 (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	674.14 Mn
10	Entera Bio	161.44 Mn	150.13 Mn	-	-

Download Data